This study aimed to estimate the costs of formal and informal care of patients with Alzheimer's disease, to compare care costs across European countries and identify potential differences in cost patterns between countries and regions.
The ICTUS study is a prospective, naturalistic observational study conducted in specialised memory clinics in 12 European countries. In total, 1385 patients diagnosed with Alzheimer's disease were enrolled at baseline. All subjects had a reliable informant (primary caregiver) and informed consent was obtained from patients or their primary caregiver.
Main outcome measures
Resource utilization data was captured with the RUD Lite (Resource Utilization in Dementia) instrument and caregiver burden with the Zarit Burden Interview (ZBI). Patient disease severity was measured with the Mini-Mental State Examination (MMSE), Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-cog), Katz’ index (PADL), Instrumental activities of daily living (IADL) scale and Neuropsychiatric inventory (NPI).
The mean annual cost of care per patient was estimated to €7,820 (95% CI: €7,194–€8,446), whereof 54% were costs of informal care, 16% direct medical costs and 30% community care costs. There were substantial differences in total resource utilization and also in the balance between formal and informal care between Northern, Western and Southern Europe. PADL scores were strongly associated with formal care costs while IADL scores correlated strongly with informal care costs.
Costs of Alzheimer's Disease are high across European countries. Activities of daily living is an important determinant of care costs. Formal care service use is lower and informal care higher in Southern Europe compared to Western and Northern Europe. Differences in resource utilization patterns are important to consider in international studies of dementia care costs as well as in economic evaluations of new treatments for dementia.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Wimo, A., L. Jonsson, and B. Winblad, An estimate of the worldwide prevalence and direct costs of dementia in 2003. Dement Geriatr Cogn Disord, 2006. 21(3): p. 175–181.
Wimo, A., L. Jönsson, and B. Winblad, An estimate of the total worldwide societal costs of dementia in 2005. Alzheimer's and Dementia, 2007. 3: p. 81–91.
Jonsson, L., et al., Determinants of costs of care for patients with Alzheimer's disease. Int J Geriatr Psychiatry, 2006. 21(5): p. 449–459.
Loveman, E., et al., The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease. Health Technol Assess, 2006. 10(1): p. iii–iv, ix–xi, 1–160.
Jonsson, L. and A. Wimo, The cost of dementia in Europe: a review of the evidence, and methodological considerations. Pharmacoeconomics, 2009. 27(5): p. 391–403.
SBU, Behandling med östrogen. SBU Rapport nr 159. 2002, Statens beredning för medicinsk utvärdering (SBU): Stockholm.
Wimo, A., G. Ljunggren, and B. Winblad, Costs of dementia and dementia care: a review. Int J Geriatr Psychiatry, 1997. 12(8): p. 841–856.
Andrieu, S., et al., Predictive factors of acute hospitalization in 134 patients with Alzheimer's disease: a one year prospective study. Int J Geriatr Psychiatry, 2002. 17(5): p. 422–426.
McKhann, G., et al., Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology, 1984. 34(7): p. 939–944.
Folstein, M.F., S.E. Folstein, and P.R. McHugh, “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 1975. 12(3): p. 189–198.
Wimo, A., et al., Evaluation of the resource utilization and caregiver time in Antidementia drug trials — a quantitative battery, in The Health Economis of dementia, A. Wimo, et al., Editors. 1998, John Wiley & Sons: London. p. 465–499.
Wimo, A. and B. Winblad, Resource utilisation in dementia: RUD Lite. Brain Aging, 2003. 3: p. 48–59.
Wimo, A. and G. Nordberg, Validity and reliability of assessments of time Comparisons of direct observations and estimates of time by the use of the resource utilization in dementia (RUD)-instrument. Arch Gerontol Geriatr, 2006.
Mohs, R.C., W.G. Rosen, and K.L. Davis, The Alzheimer's disease assessment scale: an instrument for assessing treatment efficacy. Psychopharmacol Bull, 1983. 19(3): p. 448–450.
Katz, S., et al., A standardized measure of biological and psychosocial function. JAMA, 1963. 185: p. 914–919.
Lawton, M.P. and E.M. Brody, Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist, 1969. 9(3): p. 179–186.
Cummings, J.L., et al., The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology, 1994. 44(12): p. 2308–2314.
Zarit, S.H., K.E. Reever, and J. Bach-Peterson, Relatives of the impaired elderly: correlates of feelings of burden. Gerontologist, 1980. 20(6): p. 649–655.
Eurostat (2008). Economy and finance. Comparative price levels. [cited 24may2010]; Available from: http://epp.eurostat.ec.europa.eu/tgm/table.do?tab=table&init=1&plugin=1&language=en&pcode=tsier010.
Vägverket, Vägverkets samhällsekonomiska kalkylmodell. Ekonomisk teori och värderingar. 1997, Vägverket (Swedish Road Authority): Stockholm.
Hartigan, J.A., Clustering algorithms. Wiley series in probability and mathematical statistics; A Wiley publication in applied statistics. 1975, New York: Wiley.
Sano, M., et al., The effects of galantamine treatment on caregiver time in Alzheimer's disease. Int J Geriatr Psychiatry, 2003. 18(10): p. 942–950.
Feldman, H., et al., Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden. J Am Geriatr Soc, 2003. 51(6): p. 737–744.
Wimo, A., et al., Impact of donepezil treatment for Alzheimer's disease on caregiver time. Curr Med Res Opin, 2004. 20(8): p. 1221–1225.
Waldemar, G., et al., Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer's disease. Int J Geriatr Psychiatry, 2008. 23(9): p. 979–981.
Wimo A, Jönsson L, Zbrozek A. The Resource Utilization in Dementia (RUD) Instrument Is Valid for Assessing Informal Care Time in Community-Living Patients with Dementia. J Nutr Health Aging. 2010;14(8):685–690.
Dunn, G., et al., Describing, explaining or predicting mental health care costs: a guide to regression models. Methodological review. Br J Psychiatry, 2003. 183: p. 398–404.
ON BEHALF OF THE ICTUS STUDY GROUP
ICTUS study group: B. Vellas (Toulouse), R.W. Jones (Bath), A. Burns (Manchester), R. Bullock (Swindon), A. Malick (Warwick), E. Salmon (Liege), G. Waldemar (Copenhagen), J.F. Dartigues (Bordeaux), F. Pasquier (Lille), J. Touchon (Montpellier), Ph. Robert (Nice), A.S. Rigaud (Paris), V. Camus (Tours), G. Stiens (Goettingen), L. Frölich (Mannheim), M. Tsolaki (Thessalonica), G. Frisoni (Brescia), G. Rodriguez (Genoa), A. Cherubini (Perugia), L. Spiru (Bucharest), M. Boada (Barcelona), A. Salva (Girona), E. Agéra-Morales (Cordoba), J.M. Ribera-Casado (Madrid), P.M. Lage (Pamplona), B. Winblad (Stockholm), D. Zekry (Geneva), P. Scheltens (Amsterdam), M. Olde-Rikkert (Nijmegen). Co-ordination: F. Cortes, C. Cantet, P.J. Ousset, C. Caillaud, E. Reynish
About this article
Cite this article
Gustavsson, A., Jonsson, L., Rapp, T. et al. Differences in resource use and costs of dementia care between European countries: Baseline data from the ictus study. J Nutr Health Aging 14, 648–654 (2010). https://doi.org/10.1007/s12603-010-0311-7
- cost of illness